Federal Alert: Trump Administration Signals Potential Shift on 7-OH Regulation, Easing Market Concerns

Following a White House meeting on drug policy, President Donald Trump stated his administration is "looking very seriously at natural 7‑OH and getting that approved." This statement comes after a 2025 recommendation from the FDA and HHS to classify isolated 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance. Officials had previously clarified that this recommendation would not target plain leaf kratom or the trace amounts of 7-OH naturally occurring within it, only 7-OH above a specific concentration threshold.

What President Trump likely means by “natural 7-OH” are the trace amounts occurring in plain leaf kratom that would remain legal, according to previous FDA statements. The DEA has not yet begun the formal process to classify 7-OH as a Schedule I substance.

The 'So What?' for Merchants:

• No immediate changes to the legal status of plain leaf kratom or 7-OH. President Trump's statement indicates a re-evaluation of previous recommendations for isolated 7-OH, potentially signaling a more favorable approach to natural kratom products.
• The potential for federal approval of "natural 7-OH" could signal a more stable regulatory environment, potentially easing long-term pressure on payment processors and financial institutions serving the kratom industry.
• No new shipping or logistics restrictions are indicated; the discussion is at a policy-making level regarding substance classification, not immediate operational changes.

Source: Kratom Science via Sentinel Newsroom